Company intelligence / Profile preview
Dermata Therapeutics
San Diego, California, United Statesdermatarx.com ↗
- Ownership
- Public · DRMA
- Employees
- ~8
- Development stage
- Other
01
Overview
Dermata’s lead product candidate, Xyngari™ (formerly DMT310), utilizes the proprietary Spongilla platform. It has completed enrollment in a pivotal Phase 3 trial for moderate-to-severe acne with topline results expected March 2025. Previous Phase 2b data showed statistically significant improvements on all endpoints by week four through week twelve. The company’s second program, DMT410, leverages the same technology to enable topical needle-free delivery of botulinum toxin for hyperhidrosis and aesthetic uses; it has completed two Phase I proof-of-concept studies[3][4][5][6].
- Therapeutic areas
- Dermatology
- Modalities
- Topical small molecules (derived from natural sources)Biologic delivery (topical delivery of large molecules such as botulinum toxin)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Revance Therapeutics – collaboration to evaluate topical application of Xyngari with Revance's DAXXIFY® botulinum toxin type A[4].
04
Financials
- Market cap
- $3.8M
- Total revenue
- $0
- Enterprise value
- $-637.4K
Beyond the preview
Go deeper on Dermata Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dermata Therapeutics.